Online inquiry

IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4966MR)

This product GTTS-WQ4966MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets GP gene. The antibody can be applied in Ebola virus infection research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NP_066246.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 911829
UniProt ID Q05320
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4966MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15966MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ3937MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BCD-145
GTTS-WQ10810MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA M777-16-3
GTTS-WQ14185MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-910
GTTS-WQ9269MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMMU-130
GTTS-WQ6511MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CX-072
GTTS-WQ12282MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ3109MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA APN311
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW